Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure of insider share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by several company officials on April 8, 2011, through the Company's ShareReward Plan. The purchase price was £12.23 per Ordinary share. Specific acquisitions included:
- Mr A P Witty: 41 shares
- Mr S M Bicknell: 41 shares
- Mr E J Gray: 41 shares
- Mr S A Hussain: 8 shares
- Dr D Pulman: 13 shares
- Mr D S Redfern: 41 shares
- Mrs V A Whyte: 41 shares
- Ms C Thomas: 17 shares
- Dr P J Vallance: 32 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the share transactions mentioned above in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the share price of £12.23 per Ordinary share on April 8, 2011.
- Confirm the total number of shares acquired by each listed director and executive.
- Review the terms of the Company's ShareReward Plan and its Dividend Reinvestment element.
- Check subsequent filings for any changes in the holdings of the listed individuals.